Administration of umbilical cord mesenchymal stem cells in patients with severe COVID-19 pneumonia

Guo, Zhinian; Chen, Yunlong; Luo, Xiaoyu; He, Xing; Zhang, Yong; Wang, Jiang

doi:10.1186/s13054-020-03142-8

Cited by 66 publications

(117 citation statements)

References 5 publications

Supporting

Mentioning

112

Contrasting

Order By: Relevance

“…The second clinical study by Guo et al reported that human umbilical cord-derived MSC (UC-MSC) therapy improved the clinical outcomes in 31 patients with severe COVID-19 pneumonia. 12 Clinical data and laboratory parameters showed that the oxygenation improved and the cytokine storm syndrome, a hyperinflammatory state, was attenuated in these patients treated with UC-MSC intravenous infusion at a dose of 1×10 6 cells/kg. Interestingly, there is a nonrandomized openlabel cohort study using exosomes secreted from bone marrow-derived MSCs (BM-MSCs) as treatment for severe COVID-19.…”

Section: Clinical Investigations Of Msc Administration In Covid-19mentioning

confidence: 82%

“…pneumonia. 11,12 The first study conducted by Leng et al is a pilot clinical trial in China (ChiCTR2000029990) to assess whether MSC transplantation can improve the outcome of patients with COVID-19 pneumonia. 11 In this trial, 7 confirmed COVID-19 patients, including 1 critically severe, 4 severe and 2 non-severe, received a single intravenous infusion of MSCs at a dose of 1×10 6 cells/kg body weight, respectively, and 3 other severe types were followed for placebo control.…”

Section: Clinical Investigations Of Msc Administration In Covid-19mentioning

confidence: 99%

See 1 more Smart Citation

<p>Challenges for Mesenchymal Stem Cell-Based Therapy for COVID-19</p>

Li¹,

Zhao²,

Wang³

2020

DDDT

View full text Add to dashboard Cite

The coronavirus disease 2019 (COVID-19) global pandemic continues and antiviral agents and vaccines are currently under investigation. Mesenchymal stem cell (MSC)-based therapy can be a suitable option for management of patients with COVID-19 at the urgent time of virus outbreak. Currently, MSCs are being explored against the novel infectious disease due to their therapeutic properties of anti-inflammation, immunomodulation and tissue repair and regeneration, albeit the precise mechanisms of MSC action toward COVID-19 remain unclear. To date, rigorous results from clinical trials using MSCs in human have been weakly positive. The pervasive uncertainty of using MSC therapeutic products as an effective combatant against COVID-19 requires rigorous resolution on several fronts, including MSC fate after infusion, safety issue, homing capability, and MSC resistance to the disease microenvironment. Focusing on these facets, a few important ones will be critically analyzed and addressed in this article for the development of safe and effective MSC-based therapies for COVID-19.

show abstract

Section: Clinical Investigations Of Msc Administration In Covid-19mentioning

confidence: 82%

Section: Clinical Investigations Of Msc Administration In Covid-19mentioning

confidence: 99%

<p>Challenges for Mesenchymal Stem Cell-Based Therapy for COVID-19</p>

Li¹,

Zhao²,

Wang³

2020

DDDT

View full text Add to dashboard Cite

show abstract

“…However, this study demonstrated the paracrine factors that are known to be secreted by MSCs resulted in the modulation and downregulation of the cytokine storm and assisted in the restoration of oxygenation levels. This suggests that UC-MSCs could improve the lung environment and function and the modulation of pro-inflammatory cytokines [146]. In a study performed by Ercelen et al, MSCs were transplanted into patients suffering from severe COVID-19.…”

Section: Aerosolization Of Stem Cells In Vivo and In Vitromentioning

confidence: 99%

State of the Art Review of Cell Therapy in the Treatment of Lung Disease, and the Potential for Aerosol Delivery

Brave

MacLoughlin

2020

IJMS

View full text Add to dashboard Cite

Respiratory and pulmonary diseases are among the leading causes of death globally. Despite tremendous advancements, there are no effective pharmacological therapies capable of curing diseases such as COPD (chronic obstructive pulmonary disease), ARDS (acute respiratory distress syndrome), and COVID-19. Novel and innovative therapies such as advanced therapy medicinal products (ATMPs) are still in early development. However, they have exhibited significant potential preclinically and clinically. There are several longitudinal studies published, primarily focusing on the use of cell therapies for respiratory diseases due to their anti-inflammatory and reparative properties, thereby hinting that they have the capability of reducing mortality and improving the quality of life for patients. The primary objective of this paper is to set out a state of the art review on the use of aerosolized MSCs and their potential to treat these incurable diseases. This review will examine selected respiratory and pulmonary diseases, present an overview of the therapeutic potential of cell therapy and finally provide insight into potential routes of administration, with a focus on aerosol-mediated ATMP delivery.

show abstract

“…MSCs have been used effectively to treat patients with COVID-19 in recent reports[ 50 , 107 , 108 ]. The underlying processes involve preventing the cytokine storm from occurring as well as reversing the cytokine storm in compromised patients.…”

Section: Recent Success Of Mscs For Covid-19 Patients and Clinical Trmentioning

confidence: 99%

“…The percentage and counts of lymphocyte subsets (CD3, CD4, and CD8 T cell) were increased, and the level of IL-6, TNF-α, and C-reactive protein was shown to have significantly decreased after UC-MSCs treatment. Guo et al [ 108 ] reported a 31-patient trial with UC-MSCs infusion. After the first infusion of UC-MSCs, the SARS-CoV-2 PCR results of 30 patients (96.8%) became negative after a mean time of 10.7 d (SD, 4.2 d).…”

Section: Recent Success Of Mscs For Covid-19 Patients and Clinical Trmentioning

confidence: 99%

Mesenchymal stem cells as living anti-inflammatory therapy for COVID-19 related acute respiratory distress syndrome

Lin¹,

Ichim²,

Pingle³

et al. 2020

WJSC

View full text Add to dashboard Cite

Coronavirus disease 2019 (COVID-19), a pandemic disease caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV2), is growing at an exponential rate worldwide. Manifestations of this disease are heterogeneous; however, advanced cases often exhibit various acute respiratory distress syndrome-like symptoms, systemic inflammatory reactions, coagulopathy, and organ involvements. A common theme in advanced COVID-19 is unrestrained immune activation, classically referred to as a “cytokine storm”, as well as deficiencies in immune regulatory mechanisms such as T regulatory cells. While mesenchymal stem cells (MSCs) themselves are objects of cytokine regulation, they can secrete cytokines to modulate immune cells by inducing anti-inflammatory regulatory Treg cells, macrophages and neutrophils; and by reducing the activation of T and B cells, dendritic and nature killer cells. Consequently, they have therapeutic potential for treating severe cases of COVID-19. Here we discuss the unique ability of MSCs, to act as a “living anti-inflammatory”, which can “rebalance” the cytokine/immune responses to restore equilibrium. We also discuss current MSC trials and present different concepts for optimization of MSC therapy in patients with COVID-19 acute respiratory distress syndrome.

show abstract

Administration of umbilical cord mesenchymal stem cells in patients with severe COVID-19 pneumonia

Cited by 66 publications

References 5 publications

<p>Challenges for Mesenchymal Stem Cell-Based Therapy for COVID-19</p>

<p>Challenges for Mesenchymal Stem Cell-Based Therapy for COVID-19</p>

State of the Art Review of Cell Therapy in the Treatment of Lung Disease, and the Potential for Aerosol Delivery

Mesenchymal stem cells as living anti-inflammatory therapy for COVID-19 related acute respiratory distress syndrome

Contact Info

Product

Resources

About